AC Immune SA | CIK:0001651625 | 3

  • Filed: 3/20/2018
  • Entity registrant name: AC Immune SA (CIK: 0001651625)
  • Generator: EDGARfilings PROfile
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1651625/000095010318003508/0000950103-18-003508-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1651625/000095010318003508/aciu-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001651625
  • Open this page in separate window: Click

    • ifrs-full:DisclosureOfRelatedPartyExplanatory

    15.
    Related-party transactions

    Key management including the Board of Directors (five individuals excluding the CEO) and the Executive Management (four individuals) compensation was:

      
    For the Years Ended
    December 31,
    		 
    in CHF thousands
    		 
    2017
    		  
    2016
    		  
    2015
    		 
    Short-term employee benefits
    		  
    2,463
    		   
    2,251
    		   
    1,776
    		 
    Post-employment benefits
    		  
    166
    		   
    154
    		   
    124
    		 
    Share-based compensation
    		  
    1,267
    		   
    832
    		   
    8
    		 
    Total
    		  
    3,896
    		   
    3,237
    		   
    1,908
    		 

    In April 2017, Joerg Hornstein was named the Chief Financial Officer and a member of the Executive Management. He replaced the former CFO whose tenure ended in November 2016.

    Friedrich von Bohlen and Peter Bollmann joined the Board of Directors of AC Immune in October and December 2015, respectively. Friedrich von Bohlen replaced Christof Hettich who stepped down from the Board in August 2015. Hans-Beat Guertler resigned from the board in December 2015. His position was assumed by Peter Bollmann. In November 2016, Mr. Thomas Graney joined the Board of Directors of AC Immune, replacing Mathias Hothum as his term expired.

    Short-term employee benefits comprise of salaries, bonuses, social security and expense allowances.

    257,916, 98,500, and 45,000 options were granted in 2017, 2016 and 2015, respectively, to the Executive Management of the Company. No options were granted in 2017, 2016, and 2015, respectively, to the Directors of the Company. In connection with his departure in the fourth quarter of 2016, the former Chief Financial Officer forfeited his initial 2016 grant (included in the aggregate 2016 total above), and in its place was awarded 49,250 options. The fourth quarter 2016 grant date fair value of the replacement award was CHF 674 thousand.

    The Company granted 4,023 Restricted Shares as part of a Restricted Share Award to one of our Directors in accordance with our 2016 Stock Option and Incentive Plan in 2017. No such awards were issued in 2016 and 2015.
     
    In the third quarter of fiscal 2017, the Company granted 125,332 Restricted Share Units to certain members of the Board of Directors and Executive Management. No such awards were issued in 2016 and 2015.